Troy– Author –
-
AsymBio Secures $184M to Scale Biologics CDMO Capacity for Advanced Therapies like ADCs and Bispecific Antibodies
Megaproject China Overview Shanghai-based biologics CDMO AsymBio has successfully raised approximately $184 million (1.24 billion RMB) from investors including Asymchem Group and Hillhouse Qirui. This substantial investment will drive th... -
Nanoparticle Breakthroughs: Piercing the Blood-Brain Barrier to Revolutionize CNS Disease Treatment, Including Glioblastoma
MDPI Switzerland Overview Nanoparticle-based drug delivery systems are emerging as a pivotal solution for overcoming the blood-brain barrier (BBB), a critical challenge in treating central nervous system (CNS) diseases. A recent review h... -
Unlocking mRNA LNP Design: Cholesterol Found Unnecessary for Non-Hepatic Delivery
ACS Nano USA Overview New research thoroughly dissects the functional roles of individual lipid components within mRNA lipid nanoparticles (LNPs), revealing that while ionizable lipids are critical for delivery efficacy, cholesterol is e... -
Next-Gen ADCs Show Transformative Efficacy: 46% ORR in Platinum-Resistant Gynecological Cancers, up to 50% ORR in Nasopharyngeal Cancer at AACR 2026
AACR Annual Meeting 2026 USA Overview The AACR Annual Meeting 2026 highlighted groundbreaking clinical results for next-generation Antibody-Drug Conjugates (ADCs), demonstrating significant advances in targeted cancer therapy. A combinat... -
Merck Ups 2026 Guidance on Strong Q2, KEYTRUDA Bladder Cancer Expansion, and ENFLONSIA RSV Indication Broadening Bolstering Investment Story
Simply Wall St USA Overview Merck achieved robust Q2 2026 performance and subsequently upgraded its full-year guidance, driven by key regulatory advancements. The company's investment narrative is significantly strengthened by the new bl... -
Recursion Pharmaceuticals Reports Q2 Revenue Pressure but Advances First AI-Designed Neuroscience Target with Genentech to Early Discovery
Simply Wall St USA Overview Recursion Pharmaceuticals (RXRX) reported Q2 2026 revenue pressures and ongoing losses but highlighted a significant milestone: its first neuroscience target, identified through its AI drug discovery platform ... -
C4 Therapeutics Grants Stock Options to New Employees Under Nasdaq Rule, Bolstering TPD Talent Acquisition
C4 Therapeutics, Inc. USA Overview C4 Therapeutics (C4T) announced it has granted stock options to newly hired employees under Nasdaq Listing Rule 5635(c)(4). This inducement grant is a critical component of the company's strategy to adv... -
BioMarin to Present Corporate Strategy and Pipeline at Canaccord Genuity Annual Growth Conference
BioMarin Pharmaceutical Inc. (Investor Relations) USA Overview BioMarin Pharmaceutical announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12, 2026. This investor-focused event provides ... -
C4 Therapeutics Enters New Partnership with Roche for Degrader-Antibody Conjugate (DAC) Development, Reports Strong Q2
C4 Therapeutics, Inc. USA Overview C4 Therapeutics (C4T) reported robust financial results for Q2 2026 and announced a new collaboration agreement with Roche to advance research into degrader-antibody conjugate (DAC) modalities. This str... -
Generate Biomedicines Advances Novel AI-Designed Candidate GB-4362 to Clinical Development, Pushing Tolerability Limits
Generate:Biomedicines (Blog Posts) USA Overview Generate:Biomedicines announced the advancement of its novel candidate drug, GB-4362, designed using its generative biology platform, into clinical development. This milestone exemplifies t...
